1. Home
  2. QMCO vs BDTX Comparison

QMCO vs BDTX Comparison

Compare QMCO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum Corporation

QMCO

Quantum Corporation

N/A

Current Price

$30.34

Market Cap

129.1M

Sector

Technology

ML Signal

N/A

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.82

Market Cap

104.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QMCO
BDTX
Founded
1980
2014
Country
United States
United States
Employees
N/A
21
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.1M
104.0M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
QMCO
BDTX
Price
$30.34
$1.82
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
★ $26.50
$10.00
AVG Volume (30 Days)
★ 1.6M
590.7K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
64.34
★ 130.71
EPS
N/A
★ N/A
Revenue
★ $372,827,000.00
N/A
Revenue This Year
$18.93
N/A
Revenue Next Year
$13.67
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 6.65
N/A
52 Week Low
$4.19
$1.60
52 Week High
$35.65
$4.94

Technical Indicators

Market Signals
Indicator
QMCO
BDTX
Relative Strength Index (RSI) 56.89 39.45
Support Level $5.54 $1.79
Resistance Level N/A $1.90
Average True Range (ATR) 3.07 0.08
MACD -0.34 -0.01
Stochastic Oscillator 51.03 20.00

Price Performance

Historical Comparison
QMCO
BDTX

About QMCO Quantum Corporation

Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: